The genomic landscape of phaeochromocytoma

Journal of Pathology

Volumn 236, Issue 1, 2015, Pages 78-89

  Flynn, Aidan ^a,b   Benn, Diana ^c,d   Clifton Bligh, Roderick ^c,d   Robinson, Bruce ^c,d   Trainer, Alison H ^a,e   James, Paul ^a   Hogg, Annette ^a   Waldeck, Kelly ^a   George, Joshy ^f   Li, Jason ^a   Fox, Stephen B ^a   Gill, Anthony J ^c,d   McArthur, Grant ^a,e   Hicks, Rodney J ^a,e   Tothill, Richard W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f JACKSON LABORATORY   (United States)

Author keywords

gene expression profiling; genomics; mutations; next generation sequencing; paraganglioma; phaeochromocytoma; tumour heterogeneity

Indexed keywords

PROTEIN TYROSINE KINASE;

ANEUPLOIDY; ARTICLE; CLONAL EVOLUTION; COPY NUMBER VARIATION; EPIGENETICS; EXOME; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOMICS; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; MAX GENE; MICROARRAY ANALYSIS; MUTATION RATE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ADRENAL TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PARAGANGLIOMA;

ADRENAL GLAND NEOPLASMS; BASE SEQUENCE; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84927693137     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4503     Document Type: Article

References (82)

1. Lenders JWM, Eisenhofer G, Mannelli M, et al,. Phaeochromocytoma. Lancet 2005; 366: 665-675.
2. Karagiannis A, Mikhailidis DP, Athyros VG, et al,. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 2007; 14: 935-956.
3. Welander J, Söderkvist P, Gimm O,. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18: R253-R276.
4. Ayala-Ramirez M, Feng L, Johnson MM, et al,. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011; 96: 717-725.
5. Dahia PLM,. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nature Rev Cancer 2014; 14: 108-119.
6. Burnichon N, Vescovo L, Amar L, et al,. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011; 20: 3974-3985.
7. Dahia PLM, Ross KN, Wright ME, et al,. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005; 1: 72-80.
8. Qin N, de Cubas AA, Garcia-Martin R, et al,. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: insights from MYC-associated factor X. Int J Cancer 2014; 135: 2054-2064.
9. 2 sensing and cancer. Nature Rev Cancer 2008; 8: 865-873.
10. Ladroue C, Carcenac R, Leporrier M, et al,. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359: 2685-2692.
11. Astuti D, Latif F, Dallol A, et al,. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54.
12. Baysal BE, Ferrell RE, Willett-Brozick JE, et al,. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851.
13. Burnichon N, Brière J-J, Libé R, et al,. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19: 3011-3020.
14. Hao H-X, Khalimonchuk O, Schraders M, et al,. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009; 325: 1139-1142.
15. Niemann S, Müller U,. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature 2000; 26: 268-270.
16. Clark GR, Sciacovelli M, Gaude E, et al. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab 2014; 99: E2046-2050.
17. Selak MA, Armour SM, MacKenzie ED, et al,. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85.
18. Toledo RA, Qin Y, Srikantan S, et al,. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 2013; 20: 349-359.
19. Mulligan LM, Kwok JB, Healey CS, et al,. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-460.
20. Ferner RE,. Neurofibromatosis 1. Eur J Hum Genet 2007; 15: 131-138.
21. Qin Y, Yao L, King EE, et al,. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genet 2010; 42: 229-233.
22. Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, et al,. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genet 2011; 43: 663-667.
23. Schlisio S, Kenchappa RS, Vredeveld LCW, et al,. The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008; 22: 884-893.
24. Yeh I-T, Lenci RE, Qin Y, et al,. A germline mutation of the KIF1Bβ gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 2008; 124: 279-285.
25. Yoshimoto K, Iwahana H, Fukuda A, et al,. ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 1992; 83: 1057-1062.
26. Burnichon N, Buffet A, Parfait B, et al,. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 2012; 21: 5397-5405.
27. Burnichon N, Cascon A, Schiavi F, et al,. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012; 18: 2828-2837.
28. Comino-Méndez I, de Cubas AA, Bernal C, et al,. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 2013; 22: 2169-2176.
29. Crona J, Delgado Verdugo A, Maharjan R, et al,. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab 2013; 98: E1266-E1271.
30. Oudijk L, de Krijger RR, Rapa I, et al,. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. J Clin Endocrinol Metab 2014; 99: E1376-E1380.
31. Welander J, Larsson C, Bäckdahl M, et al,. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet 2012; 21: 5406-5416.
32. Zhuang Z, Yang C, Lorenzo F, et al,. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367: 922-930.
33. Dannenberg H, Speel EJ, Zhao J, et al,. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol 2000; 157: 353-359.
34. Jarbo C, Buckley PG, Piotrowski A, et al,. Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int J Cancer 2006; 118: 1159-1164.
35. Sandgren J, Diaz de Stahl T, Andersson R, et al,. Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis. Endocr Relat Cancer 2010; 17: 561-579.
36. van Nederveen FH, Korpershoek E, deLeeuw RJ, et al,. Array-comparative genomic hybridization in sporadic benign pheochromocytomas. Endocr Relat Cancer 2009; 16: 505-513.
37. Lawrence MS, Stojanov P, Mermel CH, et al,. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
38. Alexandrov LB, Nik-Zainal S, Wedge DC, et al,. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013; 3: 246-259.
39. Gerlinger M, Rowan AJ, Horswell S, et al,. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
40. McInerney-Leo AM, Marshall MS, Gardiner B, et al,. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromocytomas and paragangliomas. Clin Endocrinol 2014; 80: 25-33.
41. Li H, Durbin R,. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
42. Trapnell C, Pachter L, Salzberg SL,. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-1111.
43. McKenna A, Hanna M, Banks E, et al,. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
44. Cibulskis K, Lawrence MS, Carter SL, et al,. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213-219.
45. Larson DE, Harris CC, Chen K, et al,. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 2012; 28: 311-317.
46. Koboldt DC, Chen K, Wylie T, et al,. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 2009; 25: 2283-2285.
47. Roth A, Ding J, Morin R, et al,. JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics 2012; 28: 907-913.
48. Van Loo P, Nordgard SH, Lingjærde OC, et al,. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010; 107: 16910-16915.
49. Amarasinghe KC, Li J, Hunter SM, et al,. Inferring copy number and genotype in tumour exome data. BMC Genomics 2014; 15: 732.
50. Heider A, Alt R,. virtualArray: a R/bioconductor package to merge raw data from different microarray platforms. BMC Bioinformatics 2013; 14: 75.
51. Wilkerson M, Waltman P,. ConsensusClusterPlus: ConsensusClusterPlus. R package version 1.20.0, 2013.
52. Smyth GK,. Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Gentleman R, Carey V, Huber W, et al (eds). Springer: New York, 2005; 473.
53. Robinson MD, McCarthy DJ, Smyth GK,. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-140.
54. McPherson A, Hormozdiari F, Zayed A, et al,. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.
55. Young RJ, Waldeck K, Martin C, et al,. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014; 27: 590-600.
56. Korbel JO, Campbell PJ,. Criteria for inference of chromothripsis in cancer genomes. Cell 2013; 152: 1226-1236.
57. Frank-Raue K, Machens A, Scheuba C, et al,. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin Endocrinol 2008; 69: 259-263.
58. Vaclavikova E, Dvorakova S, Sykorova V, et al,. RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest. Endocrine 2009; 36: 419-424.
59. Erlic Z, Hoffmann MM, Sullivan M, et al,. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2010; 95: 308-313.
60. Santoro MR, Bray SM, Warren ST,. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 2012; 7: 219-245.
61. Schneller D, Machat G, Sousek A, et al,. p19(ARF)/p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology 2011; 54: 164-172.
62. Couto JP, Daly L, Almeida A, et al,. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A 2012; 109: E2361-E2370.
63. Lõpez-Jiménez E, Gõmez-Lõpez G, Leandro-García LJ, et al,. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010; 24: 2382-2391.
64. Jiao Y, Shi C, Edil BH, et al,. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
65. Banck MS, Kanwar R, Kulkarni AA, et al,. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest 2013; 123: 2502-2508.
66. Agrawal N, Jiao Y, Sausen M, et al,. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98: E364-E369.
67. Fisher R, Horswell S, Rowan A, et al,. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol 2014; 15: 268.
68. Haering CH, Farcas A-M, Arumugam P, et al,. The cohesin ring concatenates sister DNA molecules. Nature 2008; 454: 297-301.
69. Nasmyth K., Segregating sister genomes: the molecular biology of chromosome separation. Science 2002; 297: 559-565.
70. Solomon DA, Kim T, Diaz-Martinez LA, et al,. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011; 333: 1039-1043.
71. Crasta K, Ganem NJ, Dagher R, et al,. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012; 482: 53-58.
72. Wyatt AW, Collins CC,. In brief: chromothripsis and cancer. J Pathol 2013; 231: 1-3.
73. Shen H, Laird PW,. Interplay between the cancer genome and epigenome. Cell 2013; 153: 38-55.
74. Letouzé E, Martinelli C, Loriot C, et al,. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23: 739-752.
75. Xiao M, Yang H, Xu W, et al,. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012; 26: 1326-1338.
76. Cheung N-KV, Zhang J, Lu C, et al,. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. J Am Med Assoc 2012; 307: 1062-1071.
77. Heaphy CM, de Wilde RF, Jiao Y, et al,. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333: 425.
78. Lovejoy CA, Li W, Reisenweber S, et al,. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8: e1002772.
79. Baumann C, Viveiros MM, De La Fuente R,. Loss of maternal ATRX results in centromere instability and aneuploidy in the mammalian oocyte and pre-implantation embryo. PLoS Genet 2010; 6: e1001137.
80. Shioda N, Beppu H, Fukuda T, et al,. Aberrant calcium/calmodulin-dependent protein kinase II (CaMKII) activity is associated with abnormal dendritic spine morphology in the ATRX mutant mouse brain. J Neurosci 2011; 31: 346-358.
81. Bailey ML, O'Neil NJ, van Pel DM, et al. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Mol Cancer Ther 2014; 13: 724-732.
82. Buisson R, Dion-Côté A-M, Coulombe Y, et al,. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nature Struct Mol Biol 2010; 17: 1247-1254.